Skip to main content
Beximco Pharmaceuticals Ltd. logo

Beximco Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · BXP ISIN · US0885792061 LEI · 213800IMBBD6TIOQGB56 IL Manufacturing
Open in API
Filings indexed 125 across all filing types
Latest filing 2025-01-14 Board/Management Inform…
Country BD Bangladesh
Listing IL BXP

About Beximco Pharmaceuticals Ltd.

https://www.beximcopharma.com

Beximco Pharmaceuticals Ltd. is a manufacturer of generic drugs and active pharmaceutical ingredients (APIs). The company produces a broad portfolio of over 500 products across various therapeutic categories, with a focus on providing access to affordable medicines. It has established a strong market differentiation through a range of high-tech, specialized products, including metered-dose and dry powder inhalers. Serving numerous emerging and developed markets globally, its manufacturing facilities are accredited by major international regulatory authorities, including those of the USA, European Union, Australia, and Canada.

Recent filings

Filing Released Lang Actions
Board of Directors
Board/Management Information Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement from Beximco Pharmaceuticals Ltd regarding a legal challenge to a BSEC order concerning the appointment of new independent non-executive directors to the company's board. While it discusses board composition, it is primarily a regulatory announcement regarding a legal stay and corporate governance developments, fitting best under the 'Regulatory Filings' (RNS) category as it is a general corporate announcement issued via the London Stock Exchange's RNS platform.
2025-01-14 English
Annual General Meeting Statement
AGM Information Classification · 1% confidence The document is an RNS announcement from Beximco Pharmaceuticals Limited detailing the results of their Annual General Meeting (AGM) held on 29 December 2024. It confirms that all resolutions were passed, including the approval of a cash dividend and a name change. While it mentions the Annual Report, it is not the report itself, but rather a summary of the meeting outcomes and voting results. Therefore, it falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2024-12-30 English
AGM Notification
AGM Information Classification · 1% confidence The document is an official notification from Beximco Pharmaceuticals Ltd regarding their upcoming 48th Annual General Meeting (AGM). It outlines the agenda, including the adoption of financial statements, declaration of dividends, and special resolutions. While it contains information about the meeting, it is a formal notice sent to shareholders to provide information and request their participation/votes for the meeting, which aligns perfectly with the definition of a Proxy Solicitation & Information Statement (PSI).
2024-11-19 English
Financial Results for the First Quarter
Regulatory Filings Classification · 1% confidence The document is a short announcement (under 5,000 characters) from Beximco Pharmaceuticals Limited regarding the release of their financial results for the first quarter ended 30 September 2024. It explicitly provides a link to an external PDF for the full report and functions as a notification of the report's availability rather than the full financial report itself. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2024-11-14 English
Update on Interim Order Supreme Court decision
Regulatory Filings Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement regarding a legal update concerning a Supreme Court of Bangladesh decision and the subsequent lifting of a trading suspension on AIM. It does not fit into specific categories like financial reports, dividends, or director dealings. As it is a general regulatory announcement regarding company status and legal proceedings, it falls under the RNS category.
2024-11-12 English
Further re the Temporary Suspension of Trading
Regulatory Filings Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement from Beximco Pharmaceuticals Ltd regarding a temporary suspension of trading on the AIM exchange due to ongoing legal proceedings involving a Writ Petition and the appointment of a receiver by the Supreme Court of Bangladesh. Since the document details significant legal developments and their impact on the company's trading status, it falls under the category of legal proceedings and regulatory updates. Given the specific nature of the legal updates and the suspension of trading, 'LTR' (Legal Proceedings Report) is the most accurate classification.
2024-11-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.